Get the Stockscreener App
0.72
8.33%
-0.0654
After Hours:
.72
Curanex Pharmaceuticals Inc stock is traded at $0.72, with a volume of 922.24K.
It is down -8.33% in the last 24 hours and down -87.14% over the past month.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.
See More
Previous Close:
$0.7854
Open:
$0.79
24h Volume:
922.24K
Relative Volume:
0.61
Market Cap:
$19.98M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-28.00%
1M Performance:
-87.14%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.7053
$0.79
1-Week Range:
$0.662
$1.05
52-Week Range:
$0.662
$9.1796
Curanex Pharmaceuticals Inc Stock (CURX) Company Profile
Name
Curanex Pharmaceuticals Inc
Sector
Industry
Phone
718-673-6078
Address
2 JERICHO PLAZA,, JERICHO
Compare CURX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CURX
Curanex Pharmaceuticals Inc
|
0.72 | 22.24M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Curanex Pharmaceuticals Inc Stock (CURX) Latest News
Curanex Pharmaceuticals Inc (CURX) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Curanex Pharmaceuticals Issues Shares Post-IPO - TipRanks
Curanex Pharmaceuticals issues shares in private placement and repays insider loans - Investing.com
Curanex Pharmaceuticals Inc’s Quiet Period To End on October 6th (NASDAQ:CURX) - Defense World
RXRX Stock Surges: What’s Next? - StocksToTrade
CURX Pharmaceuticals: A New Dawn or a Passing Surge? - StocksToTrade
Why Bullish Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.57% - Investing.com India
Chinese Stocks To Follow Now – September 11th - Defense World
Curanex Pharmaceuticals announces pricing of its initial public offering - MSN
Curanex Pharmaceuticals Boosts IPO Proceeds with Share Sale - TipRanks
Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters - GlobeNewswire
$17.25M IPO Complete: Biotech Curanex Pharmaceuticals Secures Full Over-Allotment Exercise at $4/Share - Stock Titan
Biopharma IPO activity slows, but 2025 returns are surging - BioWorld MedTech
Finance Watch: Ever The Outlier, Biotech Outpaces Broader Stocks - insights.citeline.com
Chinese Stocks To Watch Today – September 2nd - Defense World
Chinese Stocks To Watch Today – August 31st - Defense World
Chinese Stocks To Watch TodayAugust 31st - MarketBeat
Promising Chinese Stocks To ConsiderAugust 30th - MarketBeat
Chinese Stocks To Research – August 29th - Defense World
Wall Street Zen Upgrades Curanex Pharmaceuticals (NASDAQ:CURX) to “Hold” - Defense World
Curanex Pharmaceuticals (NASDAQ:CURX) Raised to “Hold” at Wall Street Zen - Defense World
IPO NewsUS IPO Weekly Recap: Quiet week as IPO market gears up for a busy fall - renaissancecapital.com
Curanex Pharmaceuticals closes $15 million IPO on NASDAQ - Investing.com
Curanex Pharmaceuticals Inc. (CURX) Soars 10.52% on Successful IPO - AInvest
Curanex Pharmaceuticals shares rise 7.30% premarket after closing its initial public offering of 3,750,000 shares at $4.00 per share. - AInvest
Curanex Pharmaceuticals closes $15 million IPO on NASDAQ By Investing.com - Investing.com Australia
Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering - GlobeNewswire
Curanex Pharmaceuticals' IPO: A Strategic Bet on Botanical Innovation in a Resilient Biotech Sector - AInvest
Curanex Pharmaceuticals Inc. announces closing of its initial public offering - MarketScreener
Curanex Pharmaceuticals Completes Initial Public Offering for $15 Million - AInvest
$15 Million IPO: Inflammatory Disease Biotech Curanex Launches on Nasdaq with Botanical Drug Focus - Stock Titan
Curanex Pharmaceuticals Inc(NasdaqCM: CURX) added to NASDAQ Composite Index - MarketScreener
IPO Preview | Curanex Will be Listed on 8/26/2025 - AInvest
Curanex Pharmaceuticals prices IPO at $4 per share - Investing.com
Curanex Pharmaceuticals prices IPO at $4 per share, raises $15 million By Investing.com - Investing.com South Africa
CURX Stock Price and Chart — NASDAQ:CURX - TradingView
Curanex Pharmaceuticals' Nasdaq Debut: A Cautious Bet on Botanical Innovation - AInvest
Curanex Pharmaceuticals Shares Fall in Nasdaq Debut - MarketScreener
CURX IPO NewsPreclinical biotech Curanex Pharmaceuticals prices IPO at $4, the low end of the range - renaissancecapital.com
Curanex Pharmaceuticals prices IPO at $4 per share, raises $15 million - Investing.com
Curanex Pharmaceuticals prices IPO at $4 per share By Investing.com - Investing.com UK
Curanex pharmaceuticals announces pricing of its initial public offering - MarketScreener
Curanex Pharmaceuticals announces pricing of IPO - AInvest
Curanex Pharmaceuticals Inc Stock (CURX) Financials Data
There is no financial data for Curanex Pharmaceuticals Inc (CURX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):